114 related articles for article (PubMed ID: 16211038)
1. Targeting toxic proteins for turnover.
La Spada AR; Weydt P
Nat Med; 2005 Oct; 11(10):1052-3. PubMed ID: 16211038
[No Abstract] [Full Text] [Related]
2. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration.
Waza M; Adachi H; Katsuno M; Minamiyama M; Sang C; Tanaka F; Inukai A; Doyu M; Sobue G
Nat Med; 2005 Oct; 11(10):1088-95. PubMed ID: 16155577
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy.
Adachi H; Waza M; Katsuno M; Tanaka F; Doyu M; Sobue G
Neuropathol Appl Neurobiol; 2007 Apr; 33(2):135-51. PubMed ID: 17359355
[TBL] [Abstract][Full Text] [Related]
4. Cancer: the rules of attraction.
Neckers L; Lee YS
Nature; 2003 Sep; 425(6956):357-9. PubMed ID: 14508471
[No Abstract] [Full Text] [Related]
5. Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.
Neckers L
Clin Cancer Res; 2002 May; 8(5):962-6. PubMed ID: 12006507
[No Abstract] [Full Text] [Related]
6. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Sobue G
Ann N Y Acad Sci; 2006 Nov; 1086():21-34. PubMed ID: 17185503
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG.
Ivy PS; Schoenfeldt M
Oncology (Williston Park); 2004 May; 18(5):610, 615, 619-20. PubMed ID: 15209189
[No Abstract] [Full Text] [Related]
8. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse.
Tokui K; Adachi H; Waza M; Katsuno M; Minamiyama M; Doi H; Tanaka K; Hamazaki J; Murata S; Tanaka F; Sobue G
Hum Mol Genet; 2009 Mar; 18(5):898-910. PubMed ID: 19066230
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of spinal and bulbar muscular atrophy].
Adachi H; Katsuno M; Sobue G
No To Shinkei; 2004 Sep; 56(9):772-9. PubMed ID: 15552866
[No Abstract] [Full Text] [Related]
10. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
[TBL] [Abstract][Full Text] [Related]
11. Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy.
Thomas PS; Fraley GS; Damian V; Woodke LB; Zapata F; Sopher BL; Plymate SR; La Spada AR
Hum Mol Genet; 2006 Jul; 15(14):2225-38. PubMed ID: 16772330
[TBL] [Abstract][Full Text] [Related]
12. Kennedy's disease: pathogenesis and clinical approaches.
Greenland KJ; Zajac JD
Intern Med J; 2004 May; 34(5):279-86. PubMed ID: 15151675
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic approaches to spinal and bulbar muscular atrophy.
Ranganathan S; Fischbeck KH
Trends Pharmacol Sci; 2010 Nov; 31(11):523-7. PubMed ID: 20863580
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein inhibitor shows antitumor activity.
Dunn FB
J Natl Cancer Inst; 2002 Aug; 94(16):1194-5. PubMed ID: 12189221
[No Abstract] [Full Text] [Related]
16. Heat shock protein 90 is an essential molecular chaperone for nuclear transport of glucocorticoid receptor beta.
Zhang X; Clark AF; Yorio T
Invest Ophthalmol Vis Sci; 2006 Feb; 47(2):700-8. PubMed ID: 16431970
[TBL] [Abstract][Full Text] [Related]
17. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors.
Ibrahim NO; Hahn T; Franke C; Stiehl DP; Wirthner R; Wenger RH; Katschinski DM
Cancer Res; 2005 Dec; 65(23):11094-100. PubMed ID: 16322259
[TBL] [Abstract][Full Text] [Related]
18. Administration of testosterone results in reversible deterioration in Kennedy's disease.
Kinirons P; Rouleau GA
J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):106-7. PubMed ID: 17056629
[No Abstract] [Full Text] [Related]
19. 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation.
Niikura Y; Ohta S; Vandenbeldt KJ; Abdulle R; McEwen BF; Kitagawa K
Oncogene; 2006 Jul; 25(30):4133-46. PubMed ID: 16501598
[TBL] [Abstract][Full Text] [Related]
20. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.
Workman P
Mol Cancer Ther; 2003 Feb; 2(2):131-8. PubMed ID: 12589030
[No Abstract] [Full Text] [Related]
[Next] [New Search]